A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients
- PMID: 15606472
- DOI: 10.1111/j.1600-0420.2004.00358.x
A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients
Abstract
Purpose: To evaluate the effects of dorzolamide/timolol fixed combination (D/T) compared to latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow (POBF) in primary open-angle glaucoma (POAG) patients.
Methods: Thirty patients with POAG were randomized in an open-label, cross-over study. Intraocular pressure reduction was achieved by 4 weeks medical therapy with D/T twice daily or latanoprost 0.005% dosed once in the evening. During a 4-week run-in and a 4-week wash-out period between study arms, patients ceased use of all other glaucoma medications and used timolol maleate 0.5% twice daily. Primary efficacy variables were IOP and POBF.
Results: There was no difference in baseline IOP and POBF parameters between the two study arms. Both D/T and latanoprost statistically significantly reduced IOP by 4.6 mmHg (p < 0.0001) and 3.75 mmHg (p < 0.0001) and increased POBF by 2.048 microl/second (p = 0.0030) and 2.147 microl/second (p = 0.0009), respectively. Repeated measures anova detected significant changes in POBF with treatment (p = 0.0361). Dorzolamide/timolol fixed combination statistically significantly increased pulse volume by 0.767 microl (p = 0.0087), while latanoprost therapy had no significant effect (p = 0.2407).
Conclusions: Both drugs had similar effects in terms of IOP reduction. Dorzolamide/timolol significantly increased pulse volume while latanoprost had no effect. Further studies are necessary to establish whether the enhancement of choroidal blood flow can prevent glaucoma progression.
Similar articles
-
Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.Ophthalmic Res. 2007;39(1):24-31. doi: 10.1159/000097903. Epub 2006 Dec 11. Ophthalmic Res. 2007. PMID: 17164574 Clinical Trial.
-
A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients.Curr Med Res Opin. 2006 Jan;22(1):67-73. doi: 10.1185/030079906X80215. Curr Med Res Opin. 2006. PMID: 16393432 Clinical Trial.
-
Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.J Glaucoma. 2010 Jun-Jul;19(5):331-5. doi: 10.1097/IJG.0b013e3181b4cab4. J Glaucoma. 2010. PMID: 19730119 Clinical Trial.
-
Four years later: a clinical update on latanoprost.Eur J Ophthalmol. 2003 Mar;13(2):162-75. doi: 10.1177/112067210301300208. Eur J Ophthalmol. 2003. PMID: 12696636 Review.
-
Latanoprost versus combined timolol and dorzolamide.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S148-54. doi: 10.1016/s0039-6257(02)00290-4. Surv Ophthalmol. 2002. PMID: 12204712 Review.
Cited by
-
Cardiac Hypertrophy May Be a Risk Factor for the Development and Severity of Glaucoma.Biomedicines. 2022 Mar 15;10(3):677. doi: 10.3390/biomedicines10030677. Biomedicines. 2022. PMID: 35327479 Free PMC article.
-
Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.Clin Ophthalmol. 2008 Jun;2(2):389-99. doi: 10.2147/opth.s1813. Clin Ophthalmol. 2008. PMID: 19668730 Free PMC article.
-
Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension.Drug Healthc Patient Saf. 2010;2:73-83. doi: 10.2147/dhps.s9757. Epub 2010 May 24. Drug Healthc Patient Saf. 2010. PMID: 21701619 Free PMC article.
-
Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.Clin Ophthalmol. 2009;3:593-9. doi: 10.2147/opth.s4853. Epub 2009 Nov 2. Clin Ophthalmol. 2009. PMID: 19898664 Free PMC article.
-
Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients.Clin Ophthalmol. 2010 Apr 26;4:233-41. doi: 10.2147/opth.s6372. Clin Ophthalmol. 2010. PMID: 20463789 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
